February 18, 2014

Sun Pharmaceutical Industries announced that the Food and Drug Administration has granted final approval for its generic version of Temodar temozolomide capsules in 5-mg, 20-mg, 100-mg 140-mg, 180-mg and 250-mg form.

January 16, 2014

Merck on Wednesday commended the U.S. Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation for approval of vorapaxar.

November 15, 2013

New cardiovascular health guidelines released this week could dampen the potential popularity of an up-and-coming class of cholesterol drugs, according to published reports.

September 10, 2013

The former CEO of Bausch + Lomb has been appointed president and CEO of Forest Labs, the drug maker said Tuesday.

August 12, 2013

Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.

May 6, 2013

The Food and Drug Administration has approved a new drug made by Merck for treating high cholesterol, the drug maker said.

February 26, 2013

Bausch + Lomb named Robert Bertolini as president and CFO effective immediately.

February 8, 2013

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately.

With growth in traditional pharmaceuticals expected to slow down significantly, a growing number of drug makers — branded and generic alike — see specialty drugs as their main sources of revenue for the foreseeable future. At the same time, those drug makers not invested in specialty may be looking for growth opportunities in consumer health.

January 25, 2013

Dr. Reddy's has launched a drug used for treating allergies, the generic drug maker said Friday.

July 3, 2012

Mylan has launched generic versions of two drugs to treat bipolar disorder and allergies, the company said Tuesday.

June 21, 2012

It’s been cited as one of the biggest health crises facing the United States and, if solved, the equivalent dollar value of a blockbuster drug. According to the latest statistics from pharmacy benefit manager Express Scripts, poor medication adherence costs the country $317 billion per year, an upgrade from the $290 billion calculated in a study released in 2009 by the New England Healthcare Institute.


May 23, 2012

Food and Drug Administration drug warnings can have an immediate negative impact on medication adherence among patients, even if the warnings are not safety related, according to new research sponsored by CVS Caremark.

April 30, 2012

Mylan will be barred from marketing a generic version of a Merck cardiovascular drug until the drug's patent expires, under a court ruling announced Friday.

February 17, 2012

Clarinex (desloratadine), the next-generation prescription allergy remedy to the second-generation Claritin, is 1-of-3 blockbuster prescription medicines that may make the crossover from prescription-only to over-the-counter in the near future.

February 15, 2012

The Coppertone Solar Research Center has announced the launch of two new product lines: Coppertone Sport Pro Series and Coppertone Wet ‘n Clear.

February 14, 2012

Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

January 4, 2012

Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.

November 16, 2011

Unigene Labs, a developer of peptide-based therapeutics, on Wednesday appointed Walgreens' Thomas Sabatino Jr. to its board of directors.

August 22, 2011

Walgreens on Monday named Thomas Sabatino Jr. EVP, general counsel and corporate secretary, effective Sept. 12.

April 20, 2011

Mylan has launched a generic drug for treating herpes, the company said Wednesday.

March 4, 2011

As Drug Store News suggested last month, legislation under consideration in Tennessee and Kentucky that would make the popular decongestant pseudoephedrine only available by prescription has, in fact, sparked interest in neighboring states.

February 18, 2011

PARIS — Allegra is less than a week away from reaching shelves on March 4, and with the latest allergy switch will come a significant number of Rx allergy sufferers this summer.


January 28, 2011

Though Schering-Plough’s — now Merck’s — Claritin and Johnson & Johnson’s Zyrtec product lines have dominated the over-the-counter antihistamine market, the big share of the prescription antihistamine market held by Sanofi-Aventis’ Allegra (fexofenadine hydrochloride) could give it a battering ram to bust in as well, thanks to the big break Sanofi got in the form of a Food and Drug Administration approval of an OTC switch for the drug.

January 28, 2011

A former Albertsons executive has been named the newest VP pharmacy at ECRM.